1
|
Drevon L, Maslah N, Soret-Dulphy J, Dosquet C, Ravdan O, Vercellino L, Belkhodja C, Parquet N, Brignier AC, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S. Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements. Haematologica 2021; 106:1167-1171. [PMID: 32586907 PMCID: PMC8018104 DOI: 10.3324/haematol.2020.249409] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Indexed: 11/16/2022] Open
Affiliation(s)
- Louis Drevon
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris
| | - Nabih Maslah
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris
| | - Juliette Soret-Dulphy
- France Intergroupe des Syndromes Myeloproliferatifs (FIM); APHP, Centre d'Investigations Cliniques, Hôpital Saint-Louis, F-75010 Paris
| | - Christine Dosquet
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris
| | - Odno Ravdan
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris
| | | | - Celia Belkhodja
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris
| | - Nathalie Parquet
- APHP, Service d'Aphérèse Thérapeutique, Hôpital Saint- Louis, F-75010 Paris, France
| | - Anne C Brignier
- APHP, Service d'Aphérèse Thérapeutique, Hôpital Saint- Louis, F-75010 Paris, France
| | - Marie-Helene Schlageter
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris
| | - Bruno Cassinat
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris
| | - Jean-Jacques Kiladjian
- France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris; APHP, Centre d'Investigations Cliniques, Hôpital Saint-Louis, F-75010 Paris
| | - Christine Chomienne
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris
| | - Stéphane Giraudier
- APHP, Service de Biologie Cellulaire, Hôpital Saint-Louis, F-75010 Paris; France Intergroupe des Syndromes Myeloproliferatifs (FIM); Université de Paris, U1131 INSERM, IRSL, F-75010 Paris.
| |
Collapse
|
2
|
Affiliation(s)
- Philippe Amiel
- CEEI (Comité d'évaluation éthique de l'Inserm/IRB), 101, rue de Tolbiac, 75013 Paris, France - UMR 1123 ECEVE Inserm, Université de Paris, 10, avenue de Verdun 75010 Paris, France
| | - Hervé Chneiweiss
- Comité d'éthique de l'Inserm (CEI), 101, rue de Tolbiac, 75013 Paris, France - Neuroscience Paris Seine - IBPS, Équipe Plasticité gliale et tumeurs cérébrales, UMR8246 CNRS, U1130 Inserm, Sorbonne Université, Campus Pierre et Marie Curie, 7, quai Saint Bernard, 75005 Paris, France
| | - Christine Dosquet
- CEEI (Comité d'évaluation éthique de l'Inserm/IRB), 101, rue de Tolbiac, 75013 Paris, France
| |
Collapse
|
3
|
Faille D, Lamrani L, Loyau S, Huisse MG, Bourrienne MC, Alkhaier S, Cassinat B, Boulaftali Y, Debus J, Jandrot-Perrus M, Chomienne C, Dosquet C, Ajzenberg N. Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms. Cancers (Basel) 2020; 12:cancers12040992. [PMID: 32316612 PMCID: PMC7226618 DOI: 10.3390/cancers12040992] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 04/06/2020] [Accepted: 04/11/2020] [Indexed: 01/01/2023] Open
Abstract
Myeloproliferative neoplasms (MPN) are associated with an increased risk of arterial and venous thrombosis. Pegylated-interferon alpha (IFN) and hydroxyurea (HU) are commonly used to treat MPN, but their effect on hemostasis has not yet been studied. The aim of our study was to determine whether IFN and HU impact the biological hemostatic profile of MPN patients by studying markers of endothelial, platelet, and coagulation activation. A total of 85 patients (50 polycythemia vera and 35 essential thrombocythemia) were included: 28 treated with IFN, 35 with HU, and 22 with no cytoreductive drug (non-treated, NT). Von Willebrand factor, shear-induced platelet aggregation, factor VIII coagulant activity (FVIII:C), fibrinogen, and thrombin generation with and without exogenous thrombomodulin were significantly higher in IFN-treated patients compared to NT patients, while protein S anticoagulant activity was lower. In 10 patients in whom IFN therapy was discontinued, these hemostatic biomarkers returned to the values observed in NT patients, strongly suggesting an impact of IFN therapy on endothelial and coagulation activation. Overall, our study shows that treatment with IFN is associated with significant and reversible effects on the biological hemostatic profile of MPN patients. Whether they could be associated with an increased thrombotic risk remains to be determined in further randomized clinical studies.
Collapse
Affiliation(s)
- Dorothée Faille
- INSERM UMR_S1148, Université de Paris, CEDEX 18, F-75877 Paris, France; (L.L.); (S.L.); (M.-G.H.); (M.-C.B.); (Y.B.); (M.J.-P.); (N.A.)
- Laboratoire d’Hématologie, AP-HP, Hôpital Bichat, CEDEX 18, F-75877 Paris, France;
- Correspondence:
| | - Lamia Lamrani
- INSERM UMR_S1148, Université de Paris, CEDEX 18, F-75877 Paris, France; (L.L.); (S.L.); (M.-G.H.); (M.-C.B.); (Y.B.); (M.J.-P.); (N.A.)
| | - Stéphane Loyau
- INSERM UMR_S1148, Université de Paris, CEDEX 18, F-75877 Paris, France; (L.L.); (S.L.); (M.-G.H.); (M.-C.B.); (Y.B.); (M.J.-P.); (N.A.)
| | - Marie-Geneviève Huisse
- INSERM UMR_S1148, Université de Paris, CEDEX 18, F-75877 Paris, France; (L.L.); (S.L.); (M.-G.H.); (M.-C.B.); (Y.B.); (M.J.-P.); (N.A.)
- Laboratoire d’Hématologie, AP-HP, Hôpital Bichat, CEDEX 18, F-75877 Paris, France;
| | - Marie-Charlotte Bourrienne
- INSERM UMR_S1148, Université de Paris, CEDEX 18, F-75877 Paris, France; (L.L.); (S.L.); (M.-G.H.); (M.-C.B.); (Y.B.); (M.J.-P.); (N.A.)
- Laboratoire d’Hématologie, AP-HP, Hôpital Bichat, CEDEX 18, F-75877 Paris, France;
| | - Sawsaneh Alkhaier
- Service de Biologie Cellulaire, AP-HP, Hôpital Saint Louis, CEDEX 10, F-75475 Paris, France; (S.A.); (B.C.); (C.C.); (C.D.)
| | - Bruno Cassinat
- Service de Biologie Cellulaire, AP-HP, Hôpital Saint Louis, CEDEX 10, F-75475 Paris, France; (S.A.); (B.C.); (C.C.); (C.D.)
- INSERM UMR_S1131, Université de Paris, F-75010 Paris, France
| | - Yacine Boulaftali
- INSERM UMR_S1148, Université de Paris, CEDEX 18, F-75877 Paris, France; (L.L.); (S.L.); (M.-G.H.); (M.-C.B.); (Y.B.); (M.J.-P.); (N.A.)
| | - Jérôme Debus
- Laboratoire d’Hématologie, AP-HP, Hôpital Bichat, CEDEX 18, F-75877 Paris, France;
- Laboratoire d’Hématologie, AP-HP, Hôpital Louis Mourier, CEDEX, F-92701 Colombes, France
| | - Martine Jandrot-Perrus
- INSERM UMR_S1148, Université de Paris, CEDEX 18, F-75877 Paris, France; (L.L.); (S.L.); (M.-G.H.); (M.-C.B.); (Y.B.); (M.J.-P.); (N.A.)
| | - Christine Chomienne
- Service de Biologie Cellulaire, AP-HP, Hôpital Saint Louis, CEDEX 10, F-75475 Paris, France; (S.A.); (B.C.); (C.C.); (C.D.)
- INSERM UMR_S1131, Université de Paris, F-75010 Paris, France
| | - Christine Dosquet
- Service de Biologie Cellulaire, AP-HP, Hôpital Saint Louis, CEDEX 10, F-75475 Paris, France; (S.A.); (B.C.); (C.C.); (C.D.)
- INSERM UMR_S1131, Université de Paris, F-75010 Paris, France
| | - Nadine Ajzenberg
- INSERM UMR_S1148, Université de Paris, CEDEX 18, F-75877 Paris, France; (L.L.); (S.L.); (M.-G.H.); (M.-C.B.); (Y.B.); (M.J.-P.); (N.A.)
- Laboratoire d’Hématologie, AP-HP, Hôpital Bichat, CEDEX 18, F-75877 Paris, France;
| |
Collapse
|
4
|
Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S. Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses. Haematologica 2019; 105:e95-e97. [PMID: 31413086 DOI: 10.3324/haematol.2018.215582] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Affiliation(s)
- Nabih Maslah
- APHP, Hôpital Saint Louis, Service de Biologie Cellulaire.,France Intergroupe des syndromes Myéloprolifératifs (FIM).,Université Paris-Diderot.,INSERM U1131, Centre Hayem, Hôpital Saint Louis
| | - Juliette Soret
- France Intergroupe des syndromes Myéloprolifératifs (FIM).,APHP, Hôpital Saint Louis, Centre d'Investigations Cliniques
| | - Christine Dosquet
- APHP, Hôpital Saint Louis, Service de Biologie Cellulaire.,France Intergroupe des syndromes Myéloprolifératifs (FIM).,INSERM U1131, Centre Hayem, Hôpital Saint Louis
| | | | - Célia Belkhodja
- APHP, Hôpital Saint Louis, Service de Biologie Cellulaire.,France Intergroupe des syndromes Myéloprolifératifs (FIM)
| | - Marie-Hélène Schlageter
- APHP, Hôpital Saint Louis, Service de Biologie Cellulaire.,France Intergroupe des syndromes Myéloprolifératifs (FIM).,INSERM U1131, Centre Hayem, Hôpital Saint Louis
| | - Bruno Cassinat
- APHP, Hôpital Saint Louis, Service de Biologie Cellulaire.,France Intergroupe des syndromes Myéloprolifératifs (FIM).,INSERM U1131, Centre Hayem, Hôpital Saint Louis
| | - Jean-Jacques Kiladjian
- France Intergroupe des syndromes Myéloprolifératifs (FIM).,Université Paris-Diderot.,INSERM U1131, Centre Hayem, Hôpital Saint Louis.,APHP, Hôpital Saint Louis, Centre d'Investigations Cliniques
| | - Christine Chomienne
- APHP, Hôpital Saint Louis, Service de Biologie Cellulaire.,France Intergroupe des syndromes Myéloprolifératifs (FIM).,Université Paris-Diderot.,INSERM U1131, Centre Hayem, Hôpital Saint Louis
| | - Stephane Giraudier
- APHP, Hôpital Saint Louis, Service de Biologie Cellulaire .,France Intergroupe des syndromes Myéloprolifératifs (FIM).,Université Paris-Diderot.,INSERM U1131, Centre Hayem, Hôpital Saint Louis
| |
Collapse
|
5
|
Mahevas M, Van Eeckhoudt S, Moulis G, Limal N, Languille L, Bierling P, Dossier A, Duriez F, Galicier L, Morin AS, Tamburini J, Chaoui D, Bouscary D, Jijakli AAL, Khellaf M, Vaida I, Michel M, Vercellino L, Jaddi H, Yollant A, Dosquet C, Godeau B, Chomienne C. Autologous 111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists. Br J Haematol 2019; 186:e44-e47. [PMID: 30950041 DOI: 10.1111/bjh.15890] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Matthieu Mahevas
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris-Est-Créteil (UPEC University), Créteil, France
| | - Sandrine Van Eeckhoudt
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris-Est-Créteil (UPEC University), Créteil, France
| | - Guillaume Moulis
- Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.,UMR 1027, INSERM-University of Toulouse, Toulouse, France.,CIC 1436, Toulouse University Hospital, Toulouse, France
| | - Nicolas Limal
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris-Est-Créteil (UPEC University), Créteil, France
| | - Laetitia Languille
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris-Est-Créteil (UPEC University), Créteil, France
| | - Philippe Bierling
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris-Est-Créteil (UPEC University), Créteil, France
| | - Antoine Dossier
- Department of Internal Medicine, Hôpital Bichat, Paris, France
| | - Frédéric Duriez
- Oncology - Haematology, Les Hôpitaux de Chartres, Chartres, France
| | - Lionel Galicier
- Clinical Immunology, St-Louis University Hospital, Paris, France
| | - Anne-Sophie Morin
- Department of Internal Medicine, Hopital Jean Verdier, Bondy, France
| | | | - Driss Chaoui
- Haematology, CH Victor Dupouy, Agenteuil, France
| | | | | | - Mehdi Khellaf
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris-Est-Créteil (UPEC University), Créteil, France
| | | | - Marc Michel
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris-Est-Créteil (UPEC University), Créteil, France
| | - Laetitia Vercellino
- Service de Médecine Nucléaire, Assistance Publique des Hôpitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France
| | - Hind Jaddi
- Cellular Biology, Assistance Publique des Hôpitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France
| | - Armelle Yollant
- Cellular Biology, Assistance Publique des Hôpitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France
| | - Christine Dosquet
- Cellular Biology, Assistance Publique des Hôpitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France
| | - Bertrand Godeau
- Internal Medicine, French Referral Centre for Adult Immune Cytopenia, Henri Mondor University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Université Paris-Est-Créteil (UPEC University), Créteil, France
| | - Christine Chomienne
- Cellular Biology, Assistance Publique des Hôpitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France
| |
Collapse
|
6
|
Derrieux C, Jeandel R, Martin A, Dosquet C, Cassinat B, Fouillard L. When hemolysis masks polycythemia vera. Clin Case Rep 2019; 7:438-441. [PMID: 30899467 PMCID: PMC6406212 DOI: 10.1002/ccr3.1776] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 08/04/2018] [Indexed: 12/03/2022] Open
Abstract
Although uncommon, clinicians should be aware that polycythemia vera may be masked due to hemolysis. The report of such associations could help them in clinical practice to establish an early and accurate diagnosis that may be challenging in atypical presentations of myeloproliferative neoplasms.
Collapse
Affiliation(s)
- Coralie Derrieux
- Laboratoire d'hématologieGrand Hôpital de l'Est FrancilienMeauxFrance
| | - Roland Jeandel
- Service d'anatomie et Cytologie PathologiquesGrand Hôpital de l'Est FrancilienJossignyFrance
| | | | | | - Bruno Cassinat
- Service de Biologie CellulaireHôpital Saint‐LouisParisFrance
| | - Loïc Fouillard
- Service d'hématologie CliniqueGrand Hôpital de l'Est FrancilienMeauxFrance
| |
Collapse
|
7
|
Abstract
The bone marrow microenvironment (BMM) regulates the fate of hematopoietic stem cells (HSCs) in homeostatic and pathologic conditions. In myeloid malignancies, new insights into the role of the BMM and its cellular and molecular actors in the progression of the diseases have started to emerge. In this review, we will focus on describing the major players of the HSC niche and the role of the altered niche function in myeloid malignancies, more specifically focusing on the mesenchymal stroma cell compartment.
Collapse
Affiliation(s)
- Marie Goulard
- INSERM, UMRS1131-Paris Diderot University, Saint Louis Hospital, Paris, France
| | - Christine Dosquet
- INSERM, UMRS1131-Paris Diderot University, Saint Louis Hospital, Paris, France
- Cell Biology Department, APHP, Saint Louis Hospital, Paris, France
| | - Dominique Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1, Midland Road, London, NW1 1AT, UK.
| |
Collapse
|
8
|
Goulard M, Dosquet C, Chomienne C. [Towards a personalized pretransplantation conditioning in patients with myelodysplastic syndromes]. Med Sci (Paris) 2018; 34:9-11. [PMID: 29384085 DOI: 10.1051/medsci/20183401002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Marie Goulard
- Inserm UMR-S-1131, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - Christine Dosquet
- Inserm UMR-S-1131, 1, avenue Claude Vellefaux, 75010 Paris, France - APHP, Hôpital Saint-Louis, unité de biologie cellulaire, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - Christine Chomienne
- Inserm UMR-S-1131, 1, avenue Claude Vellefaux, 75010 Paris, France - APHP, Hôpital Saint-Louis, unité de biologie cellulaire, 1, avenue Claude Vellefaux, 75010 Paris, France
| |
Collapse
|
9
|
Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 2017; 103:438-446. [PMID: 29217781 PMCID: PMC5830374 DOI: 10.3324/haematol.2017.181297] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Accepted: 12/06/2017] [Indexed: 12/12/2022] Open
Abstract
We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative neoplasms. In this study, we report their long-term outcomes and correlations with mutational patterns of driver and non-driver mutations analyzed by targeted next generation sequencing. The median age at diagnosis was 66 years old, the median follow-up since starting pegylated interferon was 58 months. At the time of analysis, 30 (48.4%) patients were alive including 16 still being treated with pegylated interferon. The median survival of patients with intermediate and high-risk prognostic Lille and dynamic International Prognostic Scoring System scores treated with pegylated interferon was increased in comparison to that of historical cohorts. In addition, overall survival was significantly correlated with the duration of pegylated interferon therapy (70 versus 30 months after 2 years of treatment, P<10−12). JAK2V617F allele burden was decreased by more than 50% in 58.8% of patients and two patients even achieved complete molecular response. Next-generation sequencing analyses performed in 49 patients showed that 28 (57.1%) of them carried non-driver mutations. The presence of at least one additional mutation was associated with a reduction of both overall and leukemia-free survival. These findings in a large series of patients with myelofibrosis suggest that pegylated interferon therapy may provide a survival benefit for patients with intermediate- or high-risk Lille and dynamic International Prognostic Scoring System scores. It also reduced the JAK2V617F allele burden in most patients. These results further support the use of pegylated interferon in selected patients with myelofibrosis.
Collapse
Affiliation(s)
| | - Aurélie Chauveau
- Laboratoire d'Hématologie, CHRU de Brest and INSERM U1078, Université de Bretagne Occidentale, Brest, France
| | | | - Emmanuel Gyan
- Hématologie et Thérapie Cellulaire, CRU de Cancérologie H.S. Kaplan, Tours, France
| | | | | | - Jean-Loup Demory
- Service d'Hématologie, Hôpital St Vincent de Paul, Lille, France
| | | | | | - Jerome Rey
- Département d'Hématologie, Institut Paoli-Calmette, Marseille, France
| | - Lydia Roy
- Service d'Hématologie, Hôpital de Créteil, France
| | | | - Laurent Knoops
- Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium
| | | | - Mohamed Malou
- Service d'Oncologie et D'Hématologie, Hôpital de Morlaix, France
| | - Pascal Hutin
- Service de Médecine Interne et de Maladies Infectieuses, Hôpital Laennec, Quimper, France
| | - Dana Ranta
- Département d'Hématologie, Hôpital Universitaire de Nancy, Vandoeuvre-lès-Nancy, France
| | - Omar Benbrahim
- Service d'Hématologie, Hôpital La Source, Orléans, France
| | - Valérie Ugo
- Laboratoire d'Hématologie, CHU d'Angers, France
| | - Eric Lippert
- Laboratoire d'Hématologie, CHRU de Brest and INSERM U1078, Université de Bretagne Occidentale, Brest, France
| | - Jean-Jacques Kiladjian
- Centre d'Investigation Clinique, Hôpital Saint-Louis, APHP, Université Paris Diderot, Inserm, Paris, France
| |
Collapse
|
10
|
Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti GJ, Bonnet D. Preclinical modeling of myelodysplastic syndromes. Leukemia 2017; 31:2702-2708. [PMID: 28663577 PMCID: PMC5729336 DOI: 10.1038/leu.2017.172] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Revised: 04/25/2017] [Accepted: 05/23/2017] [Indexed: 12/12/2022]
Abstract
Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both models. The level of engraftment was patient specific with no correlation to any specific MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our in vitro system, we have been able to co-culture CD34+ cells from MDS patient BM on auto- and/or allogeneic MSCs over 4 weeks with a fold expansion of up to 600 times. More importantly, these expanded cells conserved their MDS clonal architecture as well as genomic integrity.
Collapse
Affiliation(s)
- K Rouault-Pierre
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| | - S A Mian
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
| | - M Goulard
- INSERM, UMRS1131–University Paris Diderot, Saint Louis Hospital, Paris, France
| | - A Abarrategi
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| | - A Di Tulio
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| | - A E Smith
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
- King’s College Hospital, Department of Haematology, London, UK
| | - A Mohamedali
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
| | - S Best
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
| | - A-M Nloga
- Senior Haematology Department, Saint Louis Hospital, APHP, Paris, France
| | | | - L Ades
- Senior Haematology Department, Saint Louis Hospital, APHP, Paris, France
| | - C Chomienne
- INSERM, UMRS1131–University Paris Diderot, Saint Louis Hospital, Paris, France
- Cell Biology Department, Saint Louis Hospital, APHP, Paris, France
| | - P Fenaux
- INSERM, UMRS1131–University Paris Diderot, Saint Louis Hospital, Paris, France
- Senior Haematology Department, Saint Louis Hospital, APHP, Paris, France
| | - C Dosquet
- INSERM, UMRS1131–University Paris Diderot, Saint Louis Hospital, Paris, France
- Cell Biology Department, Saint Louis Hospital, APHP, Paris, France
| | - G J Mufti
- King’s College London School of Medicine, Department of Haematological Medicine, London, UK
- King’s College Hospital, Department of Haematology, London, UK
| | - D Bonnet
- Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, UK
| |
Collapse
|
11
|
Djeghloul D, Kuranda K, Kuzniak I, Barbieri D, Naguibneva I, Choisy C, Bories JC, Dosquet C, Pla M, Vanneaux V, Socié G, Porteu F, Garrick D, Goodhardt M. Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation. Stem Cell Reports 2017; 6:970-984. [PMID: 27304919 PMCID: PMC4911502 DOI: 10.1016/j.stemcr.2016.05.007] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Revised: 05/13/2016] [Accepted: 05/16/2016] [Indexed: 01/11/2023] Open
Abstract
The capacity of hematopoietic stem cells (HSC) to generate B lymphocytes declines with age, contributing to impaired immune function in the elderly. Here we show that the histone methyltransferase SUV39H1 plays an important role in human B lymphoid differentiation and that expression of SUV39H1 decreases with age in both human and mouse HSC, leading to a global reduction in H3K9 trimethylation and perturbed heterochromatin function. Further, we demonstrate that SUV39H1 is a target of microRNA miR-125b, a known regulator of HSC function, and that expression of miR-125b increases with age in human HSC. Overexpression of miR-125b and inhibition of SUV39H1 in young HSC induced loss of B cell potential. Conversely, both inhibition of miR-125 and enforced expression of SUV39H1 improved the capacity of HSC from elderly individuals to generate B cells. Our findings highlight the importance of heterochromatin regulation in HSC aging and B lymphopoiesis.
Collapse
Affiliation(s)
- Dounia Djeghloul
- INSERM UMRS-1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France
| | - Klaudia Kuranda
- INSERM UMRS-1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France
| | - Isabelle Kuzniak
- INSERM UMRS-1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France
| | - Daniela Barbieri
- INSERM UMRS-1170, Gustave Roussy Cancer Campus, Université Paris Sud - Université Paris-Saclay, Villejuif, France
| | - Irina Naguibneva
- INSERM UMRS-967, Institut de Radiobiologie Cellulaire et Moléculaire, Commissariat à l'Energie Atomique, Fontenay-aux-Roses, France
| | - Caroline Choisy
- INSERM UMRS-1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France
| | - Jean-Christophe Bories
- INSERM UMRS-1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France
| | - Christine Dosquet
- INSERM UMRS-1131, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France
| | - Marika Pla
- INSERM UMRS-1131, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France
| | - Valérie Vanneaux
- AP-HP Unité de Thérapie Cellulaire, Centre d'Investigation Clinique en Biothérapie Cellulaire and INSERM UMRS-1160, Université Paris Diderot, Paris, France
| | - Gérard Socié
- AP-HP Hematology Transplantation and INSERM UMRS-1160, Université Paris Diderot, Paris, France
| | - Françoise Porteu
- INSERM UMRS-1170, Gustave Roussy Cancer Campus, Université Paris Sud - Université Paris-Saclay, Villejuif, France
| | - David Garrick
- INSERM UMRS-1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France
| | - Michele Goodhardt
- INSERM UMRS-1126, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France.
| |
Collapse
|
12
|
Mian S, Rouault-Pierre K, Goulard M, Fenaux P, Dosquet C, Mufti G, Bonnet D. Preclinical modeling of myelodysplastic syndromes. Exp Hematol 2017. [DOI: 10.1016/j.exphem.2017.06.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
13
|
Vercellino L, Ouvrier MJ, Barré E, Cassinat B, de Beco V, Dosquet C, Chevret S, Meignin V, Chomienne C, Toubert ME, Merlet P, Kiladjian JJ. Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET. J Nucl Med 2017; 58:1603-1608. [PMID: 28360204 DOI: 10.2967/jnumed.116.188508] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2016] [Accepted: 03/20/2017] [Indexed: 11/16/2022] Open
Abstract
An emerging noninvasive approach to assess tissue proliferation uses the PET tracer 3'-deoxy-3'-18F-fluorothymidine (18F-FLT). To evaluate the diagnostic value of this technique in myelofibrosis, 18F-FLT PET imaging results were compared with bone marrow histology and bone marrow scintigraphy (BMS), the gold standard techniques in this clinical situation. Methods: Fifteen patients with histology-proven myelofibrosis were included consecutively in the study. Tracers' distributions were assessed using a visual grading assessment score of the uptake in the axial skeleton, proximal and distal limbs, liver, and spleen. This visual score was used to define patterns of tracer distribution and to compare the information provided either by PET or by BMS. A semiquantitative analysis with determination of SUVmax in the same localizations was performed for 18F-FLT PET. Results: The histology grade of fibrosis correlated with the SUVmax in the axial skeleton (spine and iliac crests) and proximal limbs. 18F-FLT uptake in these areas was much lower in patients with grade 3 fibrosis than in patients with grade 1 or 2 fibrosis. 18F-FLT PET showed the same distribution of uptake as BMS in 13 of 14 patients (1 patient did not undergo BMS). In 1 patient, 18F-FLT PET clearly showed an intense abnormal splenic uptake, whereas spleen uptake was inconclusive with BMS. Conclusion:18F-FLT PET appears to be a reliable and convenient technique to assess hematopoietic activity in bone marrow. It yields results close to those observed with BMS. In our study population, 18F-FLT uptake in the axial skeleton and proximal limbs assessed by SUVmax correlated with the grade of fibrosis. Thus, 18F-FLT PET may be a useful tool to measure the severity of myelofibrosis, and to monitor noninvasively the patients' status during follow-up. Finally, 18F-FLT PET may be foreseen as an alternative to BMS.
Collapse
Affiliation(s)
- Laetitia Vercellino
- Service de Médecine Nucléaire, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Matthieu John Ouvrier
- Service de Médecine Nucléaire, Hôpital Avicenne, Assistance-Publique Hôpitaux de Paris, Bobigny, France
| | - Emmanuelle Barré
- Service de Médecine Nucléaire, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Bruno Cassinat
- Unité de Biologie Cellulaire, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Virginie de Beco
- Service de Médecine Nucléaire, Hôpital Avicenne, Assistance-Publique Hôpitaux de Paris, Bobigny, France
| | - Christine Dosquet
- Unité de Biologie Cellulaire, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Sylvie Chevret
- Service de Biostatistique et Information Médicale, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France.,Université Paris-Diderot (Paris 7), Paris, France
| | - Véronique Meignin
- Service d'Anatomo-Pathologie, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France; and
| | - Christine Chomienne
- Unité de Biologie Cellulaire, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France.,Université Paris-Diderot (Paris 7), Paris, France
| | - Marie-Elisabeth Toubert
- Service de Médecine Nucléaire, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Pascal Merlet
- Service de Médecine Nucléaire, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris, Paris, France.,Université Paris-Diderot (Paris 7), Paris, France
| | - Jean-Jacques Kiladjian
- Université Paris-Diderot (Paris 7), Paris, France.,Centre d'Investigations Cliniques, Hôpital Saint-Louis, Assistance-Publique Hôpitaux de Paris France, Paris, France
| |
Collapse
|
14
|
Van Eeckhoudt S, Dosquet C, Moulis G, Galicier L, Dossier A, Morin A, Michel M, Bierling P, Godeau B, Limal N, Chomienne C, Mahevas M. La durée de vie des plaquettes autologues marquées à l’oxinate d’indium-111 est interprétable chez les patients avec un PTI chronique traités par agonistes du récepteur de la thrombopoiëtine. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Levy M, Molta C, Meyer O, Dosquet C, Danon F, Babron MC, Montes de Oca M. Antiphospholipid antibodies in patients with childhood onset systemic lupus erythematosus and their relatives. A French cooperative study. Contrib Nephrol 2015; 99:26-34. [PMID: 1458923 DOI: 10.1159/000421686] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- M Levy
- Unité de Recherches d'Epidémiologie génétique, INSERM U-155, Paris, France
| | | | | | | | | | | | | |
Collapse
|
16
|
Lescale C, Schenten V, Djeghloul D, Bennabi M, Gaignier F, Vandamme K, Strazielle C, Kuzniak I, Petite H, Dosquet C, Frippiat JP, Goodhardt M. Hind limb unloading, a model of spaceflight conditions, leads to decreased B lymphopoiesis similar to aging. FASEB J 2014; 29:455-63. [PMID: 25376832 DOI: 10.1096/fj.14-259770] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Within the bone marrow, the endosteal niche plays a crucial role in B-cell differentiation. Because spaceflight is associated with osteoporosis, we investigated whether changes in bone microstructure induced by a ground-based model of spaceflight, hind limb unloading (HU), could affect B lymphopoiesis. To this end, we analyzed both bone parameters and the frequency of early hematopoietic precursors and cells of the B lineage after 3, 6, 13, and 21 d of HU. We found that limb disuse leads to a decrease in both bone microstructure and the frequency of B-cell progenitors in the bone marrow. Although multipotent hematopoietic progenitors were not affected by HU, a decrease in B lymphopoiesis was observed as of the common lymphoid progenitor (CLP) stage with a major block at the progenitor B (pro-B) to precursor B (pre-B) cell transition (5- to 10-fold decrease). The modifications in B lymphopoiesis were similar to those observed in aged mice and, as with aging, decreased B-cell generation in HU mice was associated with reduced expression of B-cell transcription factors, early B-cell factor (EBF) and Pax5, and an alteration in STAT5-mediated IL-7 signaling. These findings demonstrate that mechanical unloading of hind limbs results in a decrease in early B-cell differentiation resembling age-related modifications in B lymphopoiesis.
Collapse
Affiliation(s)
- Chloé Lescale
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Véronique Schenten
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Dounia Djeghloul
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Meriem Bennabi
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Fanny Gaignier
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Katleen Vandamme
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Catherine Strazielle
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Isabelle Kuzniak
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Hervé Petite
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Christine Dosquet
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Jean-Pol Frippiat
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| | - Michele Goodhardt
- *Institut Universitaire d'Hématologie, Université Paris 7 Denis Diderot, Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-940, Paris, France; EA7300, Stress Immunity Pathogens Laboratory, Lorraine University, Vandœuvre-lès-Nancy, France; and UMR CNRS 7052, Biomécanique et Biomatériaux Ostéo-articulaires, Faculté de Médecine Lariboisière, Paris, France
| |
Collapse
|
17
|
Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013; 162:783-91. [PMID: 23848933 DOI: 10.1111/bjh.12459] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Accepted: 06/06/2013] [Indexed: 01/08/2023]
Abstract
Myeloproliferative neoplasm-related myelofibrosis is associated with cytopenic or proliferative phases, splenomegaly and constitutional symptoms. Few effective treatments are available and small series suggested that interferon could be an option for myelofibrosis therapy. We performed a retrospective study of pegylated-interferon α-2a (Peg-IFNα-2a) therapy in myelofibrosis. Sixty-two patients treated with Peg-IFNα-2a at 17 French and Belgian centres were included. Responses were determined based on the criteria established by the International Working Group for Myelofibrosis Research and Treatment. Mean follow-up was 26 months. Sixteen of 25 anaemic patients (64%) (eight concomitantly receiving recombinant erythropoietin) achieved a complete response and transfusion-independence was obtained in 5/13 patients (38·5%). Constitutional symptoms resolved in 82% of patients. All five leucopenic patients normalized their leucocyte counts, whereas a normal platelet count was obtained in 5/8 thrombocytopenic patients. Splenomegaly was reduced in 46·5% of patients, and complete resolution of thrombocytosis and leucocytosis were observed in 82·8% and 68·8% of patients, respectively. Side effects (mostly haematological) were mainly of grade 1-2. The only factor independently associated with treatment failure was a spleen enlargement of more than 6 cm below the costal margin. In conclusion, Peg-IFNα-2a induced high response rates with acceptable toxicity in a large proportion of patients with primary and secondary myelofibrosis, especially in early phases.
Collapse
|
18
|
Kouroupi E, Cassinat B, Schlageter MH, Dosquet C, Kiladjian JJ, Chomienne C. Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient. Am J Hematol 2012; 87:646. [PMID: 22473461 DOI: 10.1002/ajh.23185] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2012] [Revised: 02/24/2012] [Accepted: 02/27/2012] [Indexed: 11/06/2022]
|
19
|
Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29:3907-13. [PMID: 21911721 DOI: 10.1200/jco.2011.36.0792] [Citation(s) in RCA: 182] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in randomized studies. We report final analyses from the French Polycythemia Study Group (FPSG) study, which randomly assigned HU versus pipobroman as first-line therapy in 285 patients younger than age 65 years. PATIENTS AND METHODS The full methodology has been described previously. FPSG results were updated with a median follow-up of 16.3 years. Statistical analysis was performed by using competing risks on the intention-to-treat population and according to main treatment received. RESULTS Median survival was 17 years for the whole cohort, 20.3 years for the HU arm, and 15.4 years for the pipobroman arm (P = .008) and differed significantly from that in the general population. At 10, 15, and 20 years, cumulative incidence of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) was 6.6%, 16.5%, and 24% in the HU arm and 13%, 34%, and 52% in the pipobroman arm (P = .004). Cumulative myelofibrosis incidence at 10, 15, and 20 years according to main treatment received was 15%, 24%, and 32% with HU versus 5%, 10%, and 21% with pipobroman (P = .02). CONCLUSION Data from this unique randomized trial comparing HU with another cytoreductive drug in PV showed that (1) survival of patients with PV treated with conventional agents differed from survival in the general population, (2) evolution to AML/MDS is the first cause of death, (3) pipobroman is leukemogenic and is unsuitable for first-line therapy, and (4) incidence of evolution to AML/MDS with HU is higher than previously reported, although consideration should be given to the natural evolution of PV.
Collapse
|
20
|
Kuranda K, Vargaftig J, de la Rochere P, Dosquet C, Charron D, Bardin F, Tonnelle C, Bonnet D, Goodhardt M. Age-related changes in human hematopoietic stem/progenitor cells. Aging Cell 2011; 10:542-6. [PMID: 21418508 DOI: 10.1111/j.1474-9726.2011.00675.x] [Citation(s) in RCA: 113] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Adult stem cells are critical for maintaining cellular homeostasis throughout life, yet the effects of age on their regenerative capacity are poorly understood. All lymphoid and myeloid blood cell lineages are continuously generated from hematopoietic stem cells present in human bone marrow. With age, significant changes in the function and composition of mature blood cells are observed. In this study, we report that age-related changes also occur in the human hematopoietic stem cell compartment. We find that the proportion of multipotent CD34(+) CD38(-) cells increases in the bone marrow of elderly (>70 years) individuals. CD34(+) CD38(+) CD90(-) CD45RA(+/-) CD10(-) and CD34(+) CD33(+) myeloid progenitors persist at the same level in the bone marrow, while the frequency of early CD34(+) CD38(+) CD90(-) CD45RA(+) CD10(+) and committed CD34(+) CD19(+) B-lymphoid progenitors decreases with age. In contrast to mice models of aging, transplantation experiments with immunodeficient NOD/SCID/IL-2Rγ null (NSG) mice showed that the frequency of NSG repopulating cells does not change significantly with age, and there is a decrease in myeloid lineage reconstitution. An age-related decrease in the capacity of CD34(+) cells to generate myeloid cells was also seen in colony-forming assays in vitro. Thus, with increasing age, human hematopoietic stem/progenitor cells undergo quantitative changes as well as functional modifications.
Collapse
|
21
|
|
22
|
Lescale C, Dias S, Maës J, Cumano A, Szabo P, Charron D, Weksler ME, Dosquet C, Vieira P, Goodhardt M. Reduced EBF expression underlies loss of B-cell potential of hematopoietic progenitors with age. Aging Cell 2010; 9:410-9. [PMID: 20331442 DOI: 10.1111/j.1474-9726.2010.00566.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Aging is accompanied by a reduction in the generation of B lymphocytes leading to impaired immune responses. In this study, we have investigated whether the decline in B lymphopoiesis is due to age-related defects in the hematopoietic stem cell compartment. The ability of hematopoietic stem cells from old mice to generate B cells, as measured in vitro, is decreased 2-5-fold, while myeloid potential remains unchanged. This age-related decrease in B-cell potential is more marked in common lymphoid progenitors (CLP) and was associated with reduced expression of the B-lineage specifying factors, EBF and Pax5. Notably, retrovirus-mediated expression of EBF complemented the age-related loss of B-cell potential in CLP isolated from old mice. Furthermore, transduction of CLP from old mice with a constitutively active form of STAT5 restored both EBF and Pax5 expression and increased B-cell potential. These results are consistent with a mechanism, whereby reduced expression of EBF with age decreases the frequency with which multipotent hematopoietic progenitors commit to a B-cell fate, without altering their potential to generate myeloid cells.
Collapse
Affiliation(s)
- Chloé Lescale
- Institut Universitaire d'Hématologie, Université Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Bougatef F, Menashi S, Quemener C, Naimi B, Podgorniak M, Dosquet C, Calvo FM, Lebbé C, Mourah S. EMMPRIN up-regulates VEGFR-2 through HIF-2alpha mediated mechanism: Consequences on angiogenesis and tumor progression. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, Mas VMD, Lecucq L, Kiladjian JJ, Chomienne C, Dosquet C, Parquet N, Darnige L, Porneuf M, Escoffre-Barbe M, Giraudier S, Delabesse E, Cassinat B. Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS One 2010; 5:e8893. [PMID: 20126644 PMCID: PMC2811183 DOI: 10.1371/journal.pone.0008893] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2009] [Accepted: 12/28/2009] [Indexed: 11/29/2022] Open
Abstract
Background Myeloproliferative disorders are characterized by clonal expansion of normal mature blood cells. Acquired mutations giving rise to constitutive activation of the JAK2 tyrosine kinase has been shown to be present in the majority of patients. Since the demonstration that the V617F mutation in the exon 14 of the JAK2 gene is present in about 90% of patients with Polycythemia Vera (PV), the detection of this mutation has become a key tool for the diagnosis of these patients. More recently, additional mutations in the exon 12 of the JAK2 gene have been described in 5 to 10% of the patients with erythrocytosis. According to the updated WHO criteria the presence of these mutations should be looked for in PV patients with no JAK2 V617F mutation. Reliable and accurate methods dedicated to the detection of these highly variable mutations are therefore necessary. Methods/Findings For these reasons we have defined the conditions of a High Resolution DNA Melting curve analysis (HRM) method able to detect JAK2 exon 12 mutations. After having validated that the method was able to detect mutated patients, we have verified that it gave reproducible results in repeated experiments, on DNA extracted from either total blood or purified granulocytes. This HRM assay was further validated using 8 samples bearing different mutant sequences in 4 different laboratories, on 3 different instruments. Conclusion The assay we have developed is thus a valid method, adapted to routine detection of JAK2 exon 12 mutations with highly reproducible results.
Collapse
Affiliation(s)
- Valerie Ugo
- CHU BREST, Laboratoire d'Hematologie, Brest, France
- INSERM U613, Brest, France
| | - Sylvie Tondeur
- CHU Montpellier, Laboratoire d'Hématologie, Hôpital Saint-Eloi, Montpellier, France
| | | | - Nadine Bonnin
- AP-HP, Unite de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
| | | | - Carole Tonetti
- AP-HP, Laboratoire d'Hematologie, Hopital Henri Mondor, Creteil, France
| | | | - Lydie Lecucq
- CHU BREST, Laboratoire d'Hematologie, Brest, France
| | - Jean-Jacques Kiladjian
- AP-HP, Hematology Department, Hopital Avicenne, Bobigny, France
- PV-Nord Group, Hopital Saint-Louis, Paris, France
| | - Christine Chomienne
- AP-HP, Unite de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
- PV-Nord Group, Hopital Saint-Louis, Paris, France
| | - Christine Dosquet
- AP-HP, Unite de Thérapie Cellulaire, Hopital Saint-Louis, Paris, France
| | - Nathalie Parquet
- AP-HP, Unite de Thérapie Cellulaire, Hopital Saint-Louis, Paris, France
- PV-Nord Group, Hopital Saint-Louis, Paris, France
| | - Luc Darnige
- AP-HP, Laboratoire d'Hematologie, Hopital Europeen G. Pompidou, Paris, France
| | - Marc Porneuf
- CH Le Foll, Service d'Hématologie, Saint Brieuc, France
| | | | | | - Eric Delabesse
- CHU Toulouse, Laboratoire d'Hematologie, Hôpital Purpan, Toulouse, France
| | - Bruno Cassinat
- AP-HP, Unite de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
- PV-Nord Group, Hopital Saint-Louis, Paris, France
- * E-mail:
| | | |
Collapse
|
25
|
Kouroupi E, Zoi K, Parquet N, Zoi C, Kiladjian JJ, Grigoraki V, Vainchenker W, Lellouche F, Marzac C, Schlageter MH, Dosquet C, Scott LM, Fenaux P, Loukopoulos D, Chomienne C, Cassinat B. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients. Br J Haematol 2008; 142:676-9. [DOI: 10.1111/j.1365-2141.2008.07223.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Rivet J, Mourah S, Murata H, Mounier N, Pisonero H, Mongiat-Artus P, Teillac P, Calvo F, Janin A, Dosquet C. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer 2008; 112:433-42. [PMID: 18041056 DOI: 10.1002/cncr.23186] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND Tumor angiogenesis is a dynamic process that plays a major role in cancer progression. Vascular endothelial growth factor (VEGF) and its receptors play a pivotal role in angiogenesis. The expression of VEGF and its receptors VEGFR-1 and VEGFR-2 in renal cell carcinoma (RCC) was investigated in the perspective of anti-VEGF treatments. METHODS Total VEGF protein levels were quantified by enzyme-linked immunosorbent assay (ELISA) in tumor tissue samples from surgical specimens of 65 patients with clear cell RCC. At the cellular level the VEGF isoforms VEGFR-1 and VEGFR-2 mRNA were quantified by real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) in laser-microdissected tumoral epithelial as stromal cells and in corresponding normal tissue compartments. Colocalization of VEGF and VEGFR-1 proteins was studied by triple immunofluorescent labeling. RESULTS Protein VEGF in cytosolic extracts was significantly higher in tumoral than in nontumoral tissue (P< .0001). Event-free survival was significantly longer for patients with cytosolic VEGF lower than the cutoff (75th percentile of VEGF protein levels, P= .02). In laser-microdissected epithelial cells, VEGF(121) and VEGFR-1 mRNA expressions were higher in RCC than in corresponding nontumoral kidney (P= .007 and P= .002, respectively); they were also higher in stromal cells of RCC compared with nontumoral kidney (P= .02 and P= .003, respectively). There was no differential VEGFR-2 expression in epithelial or in stromal cells of tumoral or nontumoral kidney. By immunofluorescent labeling VEGF and VEGFR-1 colocalized on RCC tumor epithelial and stromal cells. CONCLUSIONS Combined laser microdissection and quantitative RT-PCR, as triple immunofluorescent labeling, underlined the preferential expression of the most soluble VEGF isoform, VEGF(121), and its receptor VEGFR-1, but not VEGFR-2, in epithelial and stromal cells of RCC.
Collapse
Affiliation(s)
- Jacqueline Rivet
- Laboratoire de Pathologie and U728, INSERM, Université Paris 7, Hôpital Saint-Louis, AP-HP, and Institut Universitaire d'Hématologie, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Menashi S, Tribout B, Dosquet C, Le Toumelin P, Piette JC, Wechsler B, Boffa MC. Strong association between plasma thrombomodulin and pathergy test in Behcet disease. Ann Rheum Dis 2008; 67:892-3. [DOI: 10.1136/ard.2007.075143] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
28
|
Kellouche S, Martin C, Korb G, Rezzonico R, Bouard D, Benbunan M, Dubertret L, Soler C, Legrand C, Dosquet C. Tissue engineering for full-thickness burns: a dermal substitute from bench to bedside. Biochem Biophys Res Commun 2007; 363:472-8. [PMID: 17888881 DOI: 10.1016/j.bbrc.2007.08.155] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2007] [Accepted: 08/17/2007] [Indexed: 11/19/2022]
Abstract
Our aim was to obtain a viable and easily available dermal substitute (DS) for the definitive coverage of full-thickness burns. A DS composed of a collagen-glycosaminoglycan-chitosan dermal matrix (DM) colonized with foreskin fibroblasts (FF) is described. FF-colonized DS were compared to the DM seeded with adult dermal fibroblasts (DF). FF-colonized DS expressed more fibrillin and tropoelastin than that with DF. Reconstructed skin obtained with both FF- and DF-colonized DS similarly expressed laminin-5 and collagen VII at the dermal-epidermal junction. Both FF- and DF-colonized DS produced cutaneous wound healing mediators in a dose-dependent manner in the presence of platelet lysate. After freeze-thawing, the FF-colonized DS were recovered in culture and retained their ability to produce vascular endothelial growth factor. Grafting of DS into nude rats achieved a complete healing of a dermal-epidermal lesion with a good epidermalization.
Collapse
|
29
|
Kellouche S, Mourah S, Bonnefoy A, Schoëvaert D, Podgorniak MP, Calvo F, Hoylaerts MF, Legrand C, Dosquet C. Platelets, thrombospondin-1 and human dermal fibroblasts cooperate for stimulation of endothelial cell tubulogenesis through VEGF and PAI-1 regulation. Exp Cell Res 2007; 313:486-99. [PMID: 17126831 DOI: 10.1016/j.yexcr.2006.10.023] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2006] [Revised: 09/22/2006] [Accepted: 10/25/2006] [Indexed: 10/24/2022]
Abstract
During cutaneous wound repair, platelets, dermal fibroblasts (DF) and endothelial cells all cooperate. We have presently investigated the regulation of endothelial cell tubulogenesis by human platelet thrombospondin-1 (TSP-1), in comparison to transforming growth factor-beta1 (TGF-beta1) and total platelet lysates (PL), in a fibrin matrix cell culture system incorporating DF. TSP-1, TGF-beta1 and PL all stimulated VEGF expression in DF dose dependently at mRNA and protein level. TSP-1- and PL-treated DF supernatants significantly stimulated capillary-like structure formation (tubulogenesis) by dermal microvascular endothelial cells (HMEC-1 and HDMEC), in part via VEGF, as confirmed with neutralizing anti-VEGF antibodies. In contrast, TGF-beta1-treated DF supernatants did not induce tubulogenesis. This apparent discrepancy could be explained by the differential expression regulation in HMEC-1 of fibrinolysis and metalloproteinase mediators by TSP-1 and TGF-beta1. TSP-1 potently reduced the expression of plasminogen activator inhibitor-1 (PAI-1) (mRNA and protein), whereas TGF-beta1 enhanced it. The crucial role of PAI-1 in tubulogenesis was confirmed via the addition of active recombinant PAI-1, which abrogated tubulogenesis. In contrast, neutralizing PAI-1 antibodies enhanced tubulogenesis. Our results suggest that platelet TSP-1 released in a wound stimulates endothelial cell tubulogenesis through an upregulation of DF VEGF expression and a downregulation of endothelial cell PAI-1 expression.
Collapse
|
30
|
Chironi G, Dosquet C, Del-Pino M, Denarie N, Megnien JL, Drouet L, Bal dit Sollier C, Levenson J, Simon A. Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men. Am J Hypertens 2006; 19:1025-31. [PMID: 17027822 DOI: 10.1016/j.amjhyper.2006.03.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2006] [Revised: 03/23/2006] [Accepted: 03/25/2006] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Relations of mediators of inflammation and hemostasis with preclinical atherosclerosis have been poorly analyzed. The aim of this study was to test potential associations of these blood markers with indicators of cardiovascular risk and atherosclerotic burden in asymptomatic, nonsmoking, hypercholesterolemic men. METHODS A total of 87 men underwent cardiovascular risk assessment by means of 10-year Framingham risk calculation (median 9%) and atherosclerotic burden evaluation by means of ultrasonographic measurement of common carotid intima-media thickness and assessment of atherosclerotic plaques at three arterial sites (three-site plaques). RESULTS Of the markers C-reactive protein, tumor necrosis factor-alpha, interleukin-10, factor VIIc, fibrinogen, plasminogen activator inhibitor-activator, soluble intercellular adhesion molecule-1, soluble P-selectin (sP-selectin), and von Willebrand factor, only sP-selectin was positively and independently associated with high Framingham risk score (>9%) (71.7 +/- 3.6 ng/mL, n = 33 v 59.6 +/- 2.8, n = 54; mean +/- SEM; P < .05) and with three-site plaques (75.4 +/- 5.7 ng/mL, n = 14 v 62.0 +/- 2.5, n = 73; P < .05). After adjustment for all of the above markers and for cardiovascular risk factors, odd ratios of having high Framingham risk and three-site plaques were 3.38 (1.43 to 10.21) and 5.23 (1.74 to 23.52) respectively, per 1-standard deviation increase in sP-selectin. CONCLUSIONS These results confirm that among several hemostasis and inflammation mediators, only sP-selectin blood level was associated with preclinical atherosclerosis. It might confer to sP-selectin measurement a clinical usefulness for detecting and managing high cardiovascular risk in primary prevention.
Collapse
Affiliation(s)
- Gilles Chironi
- Centre de Médecine Préventive Cardiovasculaire, Hôpital Broussais, Groupe HEGP Broussais, AP-HP and Université René Descartes-Faculté de Médecine, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Lotz JP, Pautier P, Selle F, Viens P, Fabbro M, Lokiec F, Viret F, Gligorov J, Gosse B, Provent S, Ribrag V, Micléa JM, Dosquet C, Goetschel A, Cailliot C, Lefèvre G, Genève J, Lhommé C. Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. Bone Marrow Transplant 2006; 37:669-75. [PMID: 16501591 DOI: 10.1038/sj.bmt.1705310] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Topotecan has demonstrated activity in ovarian carcinomas. In order to increase the tumour response rate and to define the maximum tolerated dose (MTD) of topotecan, we decided to develop a high-dose phase I regimen supported by stem cell support. High-doses schedules using a 1-day single administration have MTDs of 10.5 (24 h continuous infusion (CI)) or 22.5 mg/m2 (30 min infusion). Five-day CI induces grade IV mucositis at high doses (MTD<12 mg/m2). We chose to administer topotecan in a 5-day schedule with a 30 min daily infusion. Patients were scheduled to receive one cycle of therapy. The first dose level was 4.0 mg/m2/day x 5 days. Limiting toxicities were defined as toxic death, grade IV non-haematopoietic or haematopoietic toxicity >6 weeks. From August 1998 to April 2002, 49 patients were included. Forty-three patients have completed one course and 15 have received two cycles. One patient treated at level 7 mg/m2/day died of sepsis. Median duration of grade IV neutropenia was 9 days. Two episodes of grade IV diarrhoea were observed at level 9.5 mg/m2/day. Pharmacokinetic data were linear within the dose range of 4-9.0 mg/m2/day. The MTD was reached at 9 mg/m2/day x 5 days.
Collapse
Affiliation(s)
- J-P Lotz
- Department of Medical Oncology, Hôpital Tenon, Assistance Publique - Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Larghero J, Rea D, Esperou H, Biscay N, Maurer MN, Lacassagne MN, Ternaux B, Traineau R, Yakouben K, Dosquet C, Socié G, Gluckman E, Benbunan M, Marolleau JP. ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery. Transfusion 2006; 46:398-402. [PMID: 16533282 DOI: 10.1111/j.1537-2995.2006.00735.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Red cell (RBC) depletion is needed to bypass ABO mismatch in allogeneic bone marrow transplantation (BMT). Technical and clinical data obtained after bone marrow (BM) processing with a continuous-flow cell separator (Cobe Spectra, Gambro BCT) are reported. STUDY DESIGN AND METHODS RBC depletion and recovery of nucleated cells, CD3+ cells, CD34+ cells, and colony-forming unit-granulocyte-macrophage were calculated. Bacteriologic contaminations, side effects of graft infusion, and hematopoietic recovery were analyzed. RESULTS A total of 114 BM samples were processed. The mean volume collected was 1099 mL (range, 390-2450 mL). Initial and residual mean RBCs volumes were 309.9 and 4.0 mL corresponding to a depletion of 98.6 +/- 0.78 percent. Before processing, the mean numbers of nucleated cells, granulocytes, CD3+ cells, CD34+ cells, and CFU-GM were 20.28 x 10(9), 12.79 x 10(9), 1.96 x 10(9), 356.7 x 10(6), and 195.6 x 10(5), respectively. The mean corresponding recoveries after processing were 33.66, 48.98, 82.02, 82.2, and 93.9 percent. Limited side effects were observed in 14 patients without correlation with residual RBCs volume. All but two patients engrafted. CONCLUSION BM processing with the Cobe Spectra cell separator provides high rates of RBC depletion without significant side effects after BMT.
Collapse
Affiliation(s)
- Jerome Larghero
- Cell Therapy Unit and Bone Marrow Transplant Department, Saint-Louis Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Pellet C, Kerob D, Dupuy A, Carmagnat MV, Mourah S, Podgorniak MP, Toledano C, Morel P, Vérola O, Dosquet C, Hamel Y, Calvo F, Rabian C, Lebbé C. Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma. J Invest Dermatol 2006; 126:621-7. [PMID: 16410791 DOI: 10.1038/sj.jid.5700083] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In order to gain further insight on the role of Kaposi's sarcoma-associated herpesvirus (KSHV) in classic and endemic Kaposi's sarcoma (KS) pathogenesis, we aimed to determine (i) whether KSHV is detectable in peripheral blood mononuclear cells (PBMCs), (ii) which PBMCs subpopulation harbor the virus, (iii) which clinical, histologic, and immunologic parameters are associated with KSHV viremia in a population of classic and endemic KS. KSHV viremia and various immunologic parameters were screened on 81 patients. KSHV viremia was positive in 58% of the patients. KSHV was detected in B cells, T cells, and monocytes. CD34+ cells depleted in circulating endothelial cells (CECs) were never infected and 50% of the patients tested had CECs infected by KSHV. We observed a significant increase of IL-2 and IFN-gamma production by CD4 T cells and an increase of IFN-gamma production by CD8 T cells compared to control patients. KS progression (P = 0.001) and KS staging (P = 0.03) were significantly and independently associated with positive KSHV viremia. Our results show that there is no specific immunosuppression in classic or endemic KS. We showed that KSHV can be detected within CECs and that KSHV viremia could be an indicator of circulating mature or precursor spindle cells.
Collapse
Affiliation(s)
- Claire Pellet
- Laboratory of Pharmacology, INSERM U716, Saint-Louis Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Wang XN, Dickinson AM, Douglas EA, Rae M, Fournier I, Dosquet C, Charron D, Gluckman E, Toubert A. EBV transformation of cells from cord blood donations: relevance to future retrospective studies on cord blood transplants. Bone Marrow Transplant 2005; 35:619-21. [PMID: 15665851 DOI: 10.1038/sj.bmt.1704790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
35
|
Abstract
Although platelet-rich plasma and platelet concentrates have been used to promote bone healing in orthopaedic and maxillofacial surgery, the underlying cellular-level mechanisms remain poorly understood. The present in vitro study investigated the effects of human platelet lysate (PL) on selected functions of cultured bone cells. Cells from 18-day-old fetal rat calvaria were isolated by a collagenase digestion procedure. PL was added at different concentrations on pre- or post-confluent cell stage. After 1 day, bone cell proliferation was maximal and half-maximal in the presence of PL from 3 x 10(8) and 0.5 x 10(8) platelets/ml, respectively. During 17 h, the number of bone cells traversing the scrape border of a scrape wound model increased by 16-fold in the presence of PL from 3 x 10(8) platelets/ml. The presence of PL from 3 x 10(8) platelets/ml in pre-confluent bone cell cultures for 48 h resulted in a threefold decrease of alkaline phosphatase (ALP) specific activity. In the case of confluent bone cells, the presence of PL (from 1 x 10(6) to 3 x 10(8) platelets/ml) for 11 days, the ALP specific activity and total calcium content decreased in a PL dose-dependent manner and reached a minimum in the presence of PL from 3 x 10(8) platelets/ml. In summary, short-term PL exposure (up to 24 h) promotes the proliferative and chemotactic bone cell functions while long-term PL exposure results in a decrease of both ALP activity and mineral formation. These data show that the soluble components contained in PL may affect the bone healing process by modulating differently bone cell functions.
Collapse
Affiliation(s)
- Emmanuel Soffer
- Laboratoire de Recherches Orthopediques, UMR-CNRS 7052, Paris, France
| | | | | | | | | |
Collapse
|
36
|
|
37
|
Rousselot P, Larghero J, Labaume S, Poupon J, Chopin M, Dosquet C, Marolleau JP, Janin A, Brouet JC, Fermand JP. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004; 72:166-71. [PMID: 14962234 DOI: 10.1046/j.0902-4441.2003.00194.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVES Pharmacological concentrations of arsenic trioxide (ATO) and organic arsenic melarsoprol induce apoptosis in malignant plasma cells. In an attempt to further document the interest of the arsenic in vivo, we treated severe combined immunodeficient (SCID) mice transplanted with human myeloma cells by ATO or melarsoprol. METHODS Fifty-two SCID mice were irradiated before intraperitoneal (i.p.) injection of plasma cells from five myeloma patients. Engraftment was assessed by serial measurement of the human monoclonal immunoglobulin G (HuMIgG) concentration in mouse serum. Treatment with ATO (10 microg/g i.p. 5 d a week), melarsoprol (30 microg/g i.p. 5 d a week) or phosphate buffer saline was started when a sustained growth of the tumor cells was demonstrated. RESULTS Seventeen mice developed the human tumor. A significant decrease in HuMIgG amounts was observed in three of five mice of the ATO group, including two that achieved an apparent complete remission persisting up to 5 months after ATO discontinuation. In these mice, no human plasma cells were detected in tissue samples collected postmortem. Soluble human interleukin-6 receptor amount, measured in mice sera as a surrogate marker of the plasma cell proliferation, varied in parallel with HuMIgG concentration. A significant difference in survival was observed between control and ATO treated mice (113 and 158 d, respectively; P = 0.01) whereas no difference could be evidenced in control and melarsoprol groups. CONCLUSION Present study confirms in vivo the in vitro effects of ATO on myeloma cells. Delayed relapses were observed suggesting that prolonged or maintenance therapy has to be considered in future clinical trials. Whether or not this will translate into clinically relevant effect of the drug in myeloma patients deserves further consideration.
Collapse
Affiliation(s)
- Philippe Rousselot
- Service Clinique des Maladies du Sang, Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Adamski H, Le Gall F, Cartron L, Dauriac C, Lancien G, Wechsler J, Ollivier I, Lachgar S, Dosquet C, Coudert MC, Chevrant-Breton J. Eruptive angiomatous lesions associated with graft-versus-host disease. Br J Dermatol 2003; 149:667-8. [PMID: 14511016 DOI: 10.1046/j.1365-2133.2003.05504.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
39
|
Senet P, Bon FX, Benbunan M, Bussel A, Traineau R, Calvo F, Dubertret L, Dosquet C. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. J Vasc Surg 2003; 38:1342-8. [PMID: 14681639 DOI: 10.1016/s0741-5214(03)00908-x] [Citation(s) in RCA: 97] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
OBJECTIVES Platelet products have been proposed as adjuvant therapy for wound healing. We undertook this study to determine the healing effect of topically applied frozen autologous platelets (FAP) on chronic venous ulcers, compared with effect of placebo, and whether use of topical FAP modifies local expression of vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF), interleukin 8 (IL-8), and tissue inhibitor of metalloproteinase-1 (TIMP-1) in wound fluid. METHODS This randomized, placebo-controlled, double-blind trial was carried out in institutional practice, with ambulatory patients with proved chronic venous leg ulcers. In all patients, whole venous blood was drawn for preparation of FAP. FAP or normal saline solution was applied three times per week for up to 12 weeks, together with hydrocolloids and standardized compression bandages. Leg ulcer surface was assessed with numerical pictures. IL-8, VEGF, KGF, and TIMP-1 levels were determined (enzyme-linked immunosorbent assay) in wound fluid after each 4 weeks of treatment. RESULTS Fifteen patients were randomized into two groups with comparable leg ulcer characteristics. Mean percent reduction in ulcer area was 26.2% in the FAP group versus 15.2% in the placebo group (P =.94). One ulcer in each group was completely healed at study end. Levels of TIMP-1 increased significantly during FAP treatment. IL-8 concentration was significantly lower in wound fluid of healing ulcers than in the fluid of nonhealing ulcers, in both FAP and placebo groups. Growth factor levels were not modified with FAP treatment. CONCLUSION Topical autologous platelets have no significant adjuvant effect on healing of chronic venous leg ulcers and increased wound fluid TIMP-1 concentration. Ulcer healing is associated with a decrease in wound fluid IL-8.
Collapse
|
40
|
Froget S, Barthelemy E, Guillot F, Soler C, Coudert MC, Benbunan M, Dosquet C. Wound healing mediator production by human dermal fibroblasts grown within a collagen-GAG matrix for skin repair in humans. Eur Cytokine Netw 2003; 14:60-4. [PMID: 12799215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
Cell and tissue therapy applications in humans are being used increasingly, particularly for tissue repair. Several reconstructed skin models have been proposed. Wound healing involves overlapping steps of inflammation, cell migration and proliferation, neovascularisation, extracellular matrix production and remodelling. This is regulated by numerous cytokines and other soluble mediators. We have prepared dermal substitutes (DS) consisting of a collagen-GAG, three-dimensional matrix colonized by human dermal fibroblasts (HDF), isolated by skin explant or enzymatic digestion of the skin for potential therapeutic use in humans. To test the functionality of these DS, we measured (ELISA) the stimulatory effect on HDF in the matrix, of serial dilutions of human serum (HS) on the production of wound healing mediators: interleukin-8 (IL-8), vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF) and tissue inhibitor of metalloproteinase-1 (TIMP-1). We observed: 1). a stimulatory effect of HS on HDF production of the different mediators tested, with a dose-dependent effect in the case of IL-8 and VEGF. 2). A matrix-potentiating effect on the production of the different mediators by HDF. 3). A decrease in the production of IL-8 and VEGF when HDF isolated by enzymatic digestion was used to colonize the matrix as compared with HDF isolated by skin explant. We conclude: 1). that the production by HDF, in a collagen-GAG matrix, of mediators involved in cutaneous wound healing is decreased when HDF are isolated by enzymatic skin digestion rather than by skin explant. 2). That measurement of the production of cytokines or other mediators could be a useful quality control to test the functionality of tissue-engineered DS for tissue repair therapy in humans and more generally of cells prepared for cell therapy.
Collapse
Affiliation(s)
- Séverine Froget
- Unité de Thérapie Cellulaire, Hôpital Saint-Louis AP-HP, 1, Avenue Claude Vellefaux 75475 Paris cedex 10, France
| | | | | | | | | | | | | |
Collapse
|
41
|
Awada A, Giacchetti S, Gerard B, Eftekhary P, Lucas C, De Valeriola D, Poullain MG, Soudon J, Dosquet C, Brillanceau MH, Giroux B, Marty M, Bleiberg H, Calvo F, Piccart M. Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. Ann Oncol 2002; 13:1925-34. [PMID: 12453862 DOI: 10.1093/annonc/mdf321] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
S 16020, a new 9-OH olivacine derivative, is a novel topoisomerase II inhibitor with activity in cell lines presenting the classical multidrug resistance phenotype. This report summarizes, in addition to pharmacokinetic data, the whole phase I clinical experience of S 16020 using three different infusion schedules. Asthenia and skin toxicity were the main side effects. In an attempt to understand the skin toxicity mechanism, experiments in animals were performed, the results of which are reported. S 16020 showed rapid tumor necrotizing activity in some patients, with soft tissue metastases of epidermoïd tumors and pain at the tumor site. To document the side effects of S 16020 and tumor site reactions (pain, edema, inflammatory signs), inflammatory parameters and some cytokines were measured. In our patients there was no hemolysis and no detection of anti-S 16020 antibodies, confirming the absence of immunogenicity of the compound. Based on the overall data of the three infusion schedules of S 16020, the dose of 100 mg/m(2) over 3 h every 3 weeks was selected for phase II studies.
Collapse
Affiliation(s)
- A Awada
- Jules Bordet Institute, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
We report a case of generalized infantile myofibromatosis with favorable outcome despite systemic involvement. Elevated urinary bFGF levels during the active phase of the disease suggested an angiogenic stimulation in the pathogenesis of myofibromatosis.
Collapse
Affiliation(s)
- C Léauté-Labrèze
- Department of Pediatric Dermatology, Pellegrin Hospital, Bordeaux, France
| | | | | | | | | | | |
Collapse
|
43
|
Abstract
We tested the immunosuppressive effect of cord blood (CB) natural killer (NK) cells using highly purified CB NK cells in mixed lymphocyte cultures (MLC) containing autologous CB T cells as responders. Control cultures were done without NK cells. Our findings revealed that CB NK cells induced a dose-dependent inhibition of T lymphocyte proliferation as evidenced by decreased 3H-thymidine incorporation in MLC. The T cell alloproliferation was significantly decreased in the presence of an NK cell to responder cell ratio of 0.1, 0.2 or 0.4 compared with control cultures done without NK cells (p=0.02, 0.003 and 0.0002, respectively). T lymphocyte inhibition was also achieved using irradiated CB NK cells and still demonstrable on addition of disparate CB NK and T cells to the MLC. In agreement with previous reports, adult blood NK cells inhibited the alloreactive T cells in the MLC using adult T lymphocytes as responders. Compared to control cultures done without NK cells, statistically significant inhibition of 3H-thymidine incorporation in MLC was observed at a ratio of NK cells to responder cells ratio of 0.2 or 0.4 (p=0.02). To investigate the mechanism whereby CB NK cells can interfere with the development of alloreactive T cells in MLC, we measured the tumour necrosis factor-alpha (TNF-alpha) concentrations in MLC supernatants using NK cell-depleted or unseparated CB mononuclear cells (MNC) as responders. The results revealed significantly high levels of TNF-alpha in the absence of NK cells (p=0.007). We conclude that CB NK cells suppress alloreactive T lymphocytes as do their counterparts in adult blood. However, the high NK to T cell ratio in CB could contribute to a more marked suppressive potential compared to that in adult blood. The mechanism of NK-mediated inhibition is likely related to disruption of the TNF-alpha pathway of T-lymphocyte activation.
Collapse
Affiliation(s)
- S El Marsafy
- Laboratoire de Recherche sur la Biologie de la Moelle Osseuse, Institut Universitaire d'Hématologie EA 1814, Paris VII, France.
| | | | | | | | | | | |
Collapse
|
44
|
Tabone MD, Landman-Parker J, Arcil B, Coudert MC, Gerota I, Benbunan M, Leverger G, Dosquet C. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res 2001; 7:538-43. [PMID: 11297245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Angiogenesis plays an important role in the growth, progression, and metastasis of solid tumors. Among angiogenic factors, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) appear to be useful markers in adults with cancer. The aim of this pilot study was to determine the levels of VEGF in serum and bFGF in serum and urine of children with solid tumor at diagnosis (as measured by ELISA), and to investigate whether these parameters provide prognostic information. Forty consecutive patients with different types of cancer were prospectively included in this study. Median values of all studied angiogenic factors were higher in patients than in controls (n = 40), and the differences were statistically significant for bFGF in serum and urine: 10 versus 3 pg/ml (P = 0.0004) and 6406 versus 0 pg/g of creatinine (P < 0.0001), respectively. Among patients, median serum values of bFGF and VEGF were higher in children with metastatic disease (n = 14) than in those with localized disease (n = 26). The difference was statistically significant for serum bFGF: 17.5 versus 6 pg/ml (P = 0.02). Serum angiogenic factor levels correlated with outcome. The estimated event-free survival at 3 years was 79% for patients with normal bFGF values (n = 13) versus 42% (n = 26; P = 0.02) for those with high levels, and 71% in case of normal VEGF values (n = 20) versus 38% (n = 19; P = 0.04) for those with high levels. No benefit of normal urinary bFGF values was observed. Our results provide a rationale for exploring the clinical interest of bFGF and VEGF measurements in body fluids of a larger group of children with cancer.
Collapse
Affiliation(s)
- M D Tabone
- Service d'Hématologie et d'Oncologie Pédiatrique, H pital d'Enfants Armand Trousseau, Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Dosquet C, Chen Y, Makke J, Miclea JM, Coudert MC, Marolleau JP, Fermand JP, Cottu P, Lotz JP, Benbunan M. Cytokines and vascular cell adhesion molecule-1 in the blood of patients undergoing HPC mobilization. Transfusion 2001; 41:206-12. [PMID: 11239224 DOI: 10.1046/j.1537-2995.2001.41020206.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND The mechanism of HPC mobilization in humans is unclear. In this study, the relationship between PBPC mobilization and blood levels of G-CSF, endogenous cytokines (IL-8, SCF, thrombopoietin [TPO]), and the vascular cell adhesion molecule-1 (VCAM-1) was analyzed in patients with malignancy who were undergoing a PBPC mobilization regimen. STUDY DESIGN AND METHODS Fifty-four patients with multiple myeloma (MM) and 29 with breast cancer (BC) underwent a mobilization regimen combining conventional chemotherapy and G-CSF up to the last day of PBPC collection. The CD34+ cell count was determined on each day when leukapheresis was scheduled. Venous blood samples (n = 117) were drawn before apheresis for CD34+ cell count (flow cytometry) and cytokine (G-CSF, IL-8, SCF, TPO) and VCAM-1 measurements (ELISA). RESULTS In multiple regression analysis, SCF was a significant determinant of CD34+ cell levels in BC patients (R = 0.50, p = 0.03) and of VCAM-1 levels in MM patients (R = 0.32, p = 0.02). SCF was negatively correlated with CD34+ cell count in patients with BC. SCF and VCAM-1 blood levels were correlated in MM and BC patients. CONCLUSION SCF and VCAM-1 could play a role in PBPC mobilization in patients and could be useful measures by which to study patients undergoing a mobilization regimen.
Collapse
Affiliation(s)
- C Dosquet
- Cell Therapy Unit and the Departments of Hematology and Oncology, Saint-Louis Hospital, Paris. France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Senet P, Coulomb B, Benbunan M, Meaume S, Dubertret L, Dosquet C. [Cell therapy: perspectives for curing skin wounds?]. Ann Dermatol Venereol 2000; 127:765-6. [PMID: 11011176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
- P Senet
- Institut de Recherche sur la Peau, Service de Dermatologie, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris Cedex 10
| | | | | | | | | | | |
Collapse
|
47
|
Castelnovo L, Dosquet C, Gaudric A, Sahel J, Hicks D. Human platelet suspension stimulates porcine retinal glial proliferation and migration in vitro. Invest Ophthalmol Vis Sci 2000; 41:601-9. [PMID: 10670494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
PURPOSE To characterize the cellular and molecular mechanisms underlying the efficacy of autologous platelet suspension adjuvant therapy in the treatment of macular hole. METHODS Platelet suspensions were: paid from whole blood samples obtained from informed volunteers. For proliferation assays, platelet suspensions or purified growth factors were added to semi-confluent cultures of porcine real glial cells for 24 hours, followed by [3H]thymidine for 15 hours, after which time cells were washed, solubilized, and counted for uptake of radioactive tracer. For cell migration assays, confluent glial cultures were scrape wounded and maintained in the presence or absence of platelet suspension or identified platelet constituents. Cell migration into the denuded area was scored as a function of time. In certain cases, specific pharmacologic inhibitors of growth factor action were added at the same time as platelet adjuvant or growth factors. RESULTS Platelet suspension adjuvant induced strong mitogenic and chemotactic responses in cultured glia, in a dose-dependent manner. Maximal incorporation of thymidine was two- to threefold that of control levels, with an ED50 approximately 5 x 10(6) platelets/ml, and migration was enhanced up to 80-fold after 48 hours. Platelet suspension-induced proliferation was completely blocked by addition of 25 microM genistein, a tyrosine kinase receptor inhibitor. However, the same concentration only partially blocked the cell migration response. Addition of any single growth factor or protein identified from ELISA analysis, or a combination of all factors, did not significantly stimulate proliferation or cell migration. CONCLUSIONS Human platelet suspensions exert both proliferative and chemotactic influences on retinal glial cells in vitro, suggesting that the same responses may occur in platelet-induced macular hole repair in humans. Growth factors or proteins that have been identified within the suspensions do not mimic these responses in vitro, implying that additional currently unidentified trophic activities are also present.
Collapse
Affiliation(s)
- L Castelnovo
- Laboratoire de Physiopathologie Rétinienne, Clinique Ophthalmologique, INSERM-Université Louis Pasteur E9918, Centre Hospitalier Régional Universitaire, Strasbourg Cedex, France
| | | | | | | | | |
Collapse
|
48
|
Paques M, Chastang C, Mathis A, Sahel J, Massin P, Dosquet C, Korobelnik JF, Le Gargasson JF, Gaudric A. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology 1999; 106:932-8. [PMID: 10328392 DOI: 10.1016/s0161-6420(99)00512-6] [Citation(s) in RCA: 132] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
OBJECTIVE To evaluate prospectively the efficacy and safety of autologous platelet concentrate (APC) as an adjuvant in surgery for idiopathic macular hole. DESIGN Multicenter, double-masked, randomized clinical trial. SETTING Four university-based ophthalmology clinics. PARTICIPANTS One hundred ten patients with stage 3 or 4 idiopathic full-thickness macular holes of less than 3 years' duration were randomized (53 eyes to the platelet group and 57 eyes to the control group). INTERVENTIONS Standardized macular hole surgery versus surgery combined with injection of an APC. In all cases, the procedure consisted of three-port pars plana vitrectomy, posterior hyaloid separation, and nonexpansile fluid-gas exchange. After the fluid-gas exchange, patients were randomized to receive either injection of an APC or no adjunctive treatment. After surgery, patients were positioned face down for 12 days. Platelet counts showed that the concentrates contained a mean of 96.106 platelets (range, 82-102). MAIN OUTCOME MEASURES Anatomic and functional evaluations were performed at 1, 3, and 6 months after surgery in a double-masked fashion by an independent observer. The main outcome was reapposition of the edge of the macular hole 1 month after surgery. Secondary outcomes were anatomic status at 3 and 6 months, changes in Early Treatment Diabetic Retinopathy Study score, and complications. RESULTS One month after surgery, the anatomic success rate in the platelet group was 52 of 53 (98%; 95% confidence interval, 0.90-1.00) versus 47 of 57 (82%; 95% confidence interval, 0.70-0.91) in the control group (P = 0.009, Fisher's exact test; relative risk, 0.11; 95% confidence interval, 0.01-0.81). Visual acuity was not significantly different between the two groups at any timepoint. There were no complications specifically attributable to the platelet injection. CONCLUSION Injection of APC improved significantly the anatomic success rate of surgery for idiopathic macular holes of less than 3 years' duration, but postoperative visual acuity of the platelet group was not statistically different from the control group.
Collapse
Affiliation(s)
- M Paques
- Department of Ophthalmology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Kerhoas Nicolas CK, Le Bidaut M, Dosquet C, Enjolras O, Stalder JF. [Kasabach-Merritt syndrome of the leg associated with osteolysis or Gorham sign]. Ann Dermatol Venereol 1998; 124:852-4. [PMID: 9732759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
INTRODUCTION Kasabach-Merritt syndrome and Gorham's sign are two uncommon and severe, sometimes life-threatening, complications in infants with vascular lesions. Their association has been described in rare cases. CASE REPORT An infant with a vast congenital angiomatous lesion including an extensive lymphatic component, developed active regional osteolysis then suddenly suffered disseminated intravascular coagulation of the leg. Medical treatment was unsatisfactory. After unsuccessful use of low molecular weight heparin, pentoxifyllin and alpha interferon, amputation of the leg was required to avoid a fatal outcome. DISCUSSION Kasabach-Merritt syndrome does not develop on classic immature hemangiomas, despite some contradictory statements in the literature. In our case, a complex tumor developed in association with a lymphatic malformation. The association of Kasabach-Merritt syndrome with osteolysis (Gorham's sign) does not appear to be fortuitous. Therapeutic management of these severe complications is difficult and requires case by case analysis.
Collapse
|
50
|
Dosquet C, Coudert MC, Wassef M, Enjolras O, Drouet L. [Importance of bFGF ("basic fibroblast growth factor") for diagnosis and treatment of hemangiomas]. Ann Dermatol Venereol 1998; 125:313-6. [PMID: 9747277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
OBJECTIVES Hemangiomas of infancy follow a characteristic three-phases course: proliferation, involution, regressed Proliferative endothelial cells predominate during the proliferative phase. Moreover it has been shown that patients with active angiogenesis have elevated levels of urinary bFGF (basic Fibroblast Growth Factor). PATIENTS AND METHODS Here we report our preliminary results of urinary bFGF assay (ELISA) for the diagnosis and follow up of severe hemangioma. We also assayed bFGF in normal infants, in patients with large vascular malformations and in infants with Kasabach-Merritt syndrome. RESULTS In the control group, urinary bFGF was elevated in new borns but nul or very low in infants. Urinary bFGF levels were normal, i.e. very low in 4 patients with a vascular malformation. In infants with a clinically proliferative hemangioma, urinary bFGF was elevated in 8 among the 10 studied. bFGF levels guided treatment in 9 patients. Urinary bFGF was elevated in 4 patients with Kasabach-Merritt syndrome. DISCUSSION Angiogenesis is regulated by angiogenic and inhibitory factors. The angiogenic factor bFGF is an autocrine growth factor for endothelial cells and hemangioma endothelial cells expressing bFGF in their cytosol during the proliferative phase. As suggested by J. Folkman and his group, assay of urinary bFGF appears useful in differentiating between hemangioma and vascular malformation and for follow up of treated patients.
Collapse
Affiliation(s)
- C Dosquet
- ETS AP-HP Site transfusionnel Saint-Louis, Laboratoire des cytokines, Paris
| | | | | | | | | |
Collapse
|